INCPF (InnoCare Pharma) Ending Cash Position: $639.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCPF InnoCare Pharma Ltd INCPF
83 GF Score
Price $1.55
GF Value $2.32
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Ending Cash Position?

InnoCare Pharma INCPF 83 Ending Cash Position is $639.8 Mil as of Dec. 2025. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review.

InnoCare Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 was $639.8 Mil.

InnoCare Pharma's quarterly Ending Cash Position increased from Dec. 2024 ($124.5 Mil) to Jun. 2025 ($654.7 Mil) but then declined from Jun. 2025 ($654.7 Mil) to Dec. 2025 ($639.8 Mil).

InnoCare Pharma's annual Ending Cash Position increased from Dec. 2023 ($588.6 Mil) to Dec. 2024 ($642.7 Mil) but then declined from Dec. 2024 ($642.7 Mil) to Dec. 2025 ($639.8 Mil).

InnoCare Pharma Ending Cash Position Related Terms

InnoCare Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Ending Cash Position Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 508.30 599.57 588.58 642.72 639.83

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -188.99 520.08 124.50 654.67 639.83
INCPF
83GF Score
InnoCare Pharma Ltd INCPF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCare Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

InnoCare Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=664.395+-24.569
=639.8

InnoCare Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=667.423+-27.597
=639.8

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $639.8 Mil mean?
InnoCare Pharma (INCPF) has a Ending Cash Position of $639.8 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on InnoCare Pharma and its competitors.
Is InnoCare Pharma's Ending Cash Position too high?
InnoCare Pharma's current Ending Cash Position is $639.8 Mil. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Ending Cash Position compare to VRTX and REGN?
InnoCare Pharma's Ending Cash Position of $639.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current Ending Cash Position is $639.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Ending Cash Position of $639.8 Mil. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Ending Cash Position is $639.8 Mil. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Ending Cash Position is $639.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (INCPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.

Key valuation signals for INCPF:

  • Ending Cash Position: $639.8 Mil
  • GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score

Get the complete analysis for INCPF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.32
GF Value